Literature DB >> 2785397

Antitumour potential of pleural cavity macrophages in lung cancer patients without malignant effusion.

S Kimura1, S Sone, K Takahashi, T Uyama, T Ogura, Y Monden.   

Abstract

The present study was undertaken to examine whether the presence of primary lung cancer could affect the antitumour activities of pleural cavity macrophages (PCM) and peripheral blood monocytes (PBM). PCM by pleural lavage and PBM were simultaneously obtained from 14 lung cancer patients not showing invasion of the pleural cavity. PCM and PBM were isolated by percoll gradient centrifugation and adherence. The lavage method yielded about 16.8 +/- 9.6 (s.e.) x 10(6) cells, which consisted of 80.7% PCM, 17.6% lymphocytes and 1.6% other cells. The cytotoxic activities of PCM and PBM against allogeneic melanoma (A375) cells were assessed by a 72h 125I-IUdR release assay. The lavaged PCM showed spontaneously high tumour cytotoxic activity which was dependent on the effector/target ratio. In 13 out of 14 cancer patients, PCM were significantly more cytotoxic to melanoma cells than PBM. In contrast, there were no significant differences in production of tumour necrosis factor (TNF-alpha) or interleukin 1 (IL-1) between PCM and PBM. When the abilities of PCM and PBM of the same patient to produce these monokines were compared, PCM produced much more TNF-alpha than PBM, thus indicating a correlation between the expression of spontaneous macrophage-mediated cytotoxicity and spontaneous TNF-alpha production by PCM. These results suggest that PCM may play an important role in host defence against invasion of the pleural cavity by cancer cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2785397      PMCID: PMC2247139          DOI: 10.1038/bjc.1989.109

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  37 in total

1.  The origin of pulmonary macrophages.

Authors:  A Blussé van Oud Alblas; R van Furth
Journal:  Immunobiology       Date:  1982-04       Impact factor: 3.144

2.  Human pulmonary macrophage tumor cell cytotoxicity.

Authors:  P Lemarbre; J Hoidal; R Vesella; J Rinehart
Journal:  Blood       Date:  1980-04       Impact factor: 22.113

3.  Tumoricidal activity of macrophages isolated from human ascitic and solid ovarian carcinomas: augmentation by interferon, lymphokines and endotoxin.

Authors:  G Peri; N Polentarutti; C Sessa; C Mangioni; A Mantovani
Journal:  Int J Cancer       Date:  1981-08-15       Impact factor: 7.396

4.  Cytotoxicity on tumor cells of peripheral blood monocytes and tumor-associated macrophages in patients with ascites ovarian tumors.

Authors:  A Mantovani; N Polentarutti; G Peri; Z B Shavit; A Vecchi; G Bolis; C Mangioni
Journal:  J Natl Cancer Inst       Date:  1980-06       Impact factor: 13.506

5.  Human alveolar macrophages: potentiation of their tumoricidal activity by liposome-encapsulated muramyl dipeptide.

Authors:  S Sone; E Tsubura
Journal:  J Immunol       Date:  1982-09       Impact factor: 5.422

6.  In vitro generation of tumoricidal properties in human alveolar macrophages following interaction with endotoxin.

Authors:  S Sone; S Moriguchi; E Shimizu; F Ogushi; E Tsubura
Journal:  Cancer Res       Date:  1982-06       Impact factor: 12.701

7.  Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide.

Authors:  E S Kleinerman; K L Erickson; A J Schroit; W E Fogler; I J Fidler
Journal:  Cancer Res       Date:  1983-05       Impact factor: 12.701

8.  Abnormal monocyte chemotaxis in patients with breast cancer: evidence for a tumor-mediated effect.

Authors:  R Snyderman; L Meadows; W Holder; S Wells
Journal:  J Natl Cancer Inst       Date:  1978-04       Impact factor: 13.506

9.  Activation of rat alveolar macrophages to the tumoricidal state in the presence of progressively growing pulmonary metastases.

Authors:  S Sone; I J Fidler
Journal:  Cancer Res       Date:  1981-06       Impact factor: 12.701

10.  Resistance of neoplasms to immunological destruction: role of a macrophage chemotaxis inhibitor.

Authors:  G R Pasternack; R Snyderman; M C Pike; R J Johnson; H S Shin
Journal:  J Exp Med       Date:  1978-07-01       Impact factor: 14.307

View more
  6 in total

1.  Differential effects of human blood monocytes on the growth of human tumour cell lines in vitro.

Authors:  H J Parry; R C Rees
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  Pleural macrophages are the dominant cell population in the thoracic cavity with an inflammatory cytokine profile similar to peritoneal macrophages.

Authors:  Akihiro Shimotakahara; Joachim F Kuebler; Gertrud Vieten; Martin L Metzelder; Claus Petersen; Benno M Ure
Journal:  Pediatr Surg Int       Date:  2007-05       Impact factor: 1.827

Review 3.  Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation.

Authors:  Jonathan E Schoenhals; Steven N Seyedin; Clark Anderson; Eric D Brooks; Yun R Li; Ahmed I Younes; Sharareh Niknam; Ailin Li; Hampartsoum B Barsoumian; Maria Angelica Cortez; James W Welsh
Journal:  Transl Lung Cancer Res       Date:  2017-04

4.  Tumor cytotoxicity and interleukin 1 production of blood monocytes of lung cancer patients.

Authors:  S Sone; T Utsugi; P Tandon; H Yanagawa; A Okubo; T Ogura
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

5.  Interleukin-2-inducible killer activity and its regulation by blood monocytes from autologous lymphocytes of lung cancer patients.

Authors:  S Sone; E Kunishige; F Fawzy; H Yanagawa; A Nii; K Maeda; S Atagi; Y Heike; Y Nishioka; K Mizuno
Journal:  Jpn J Cancer Res       Date:  1991-06

6.  Production of tumor necrosis factor-alpha by alveolar macrophages of lung cancer patients.

Authors:  A Okubo; S Sone; S M Singh; T Ogura
Journal:  Jpn J Cancer Res       Date:  1990-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.